Chronic lymphocytic leukaemia trials in Spain

42 of 43 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

• Phase 1/2Taking people
  Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

  Where

  Barcelona, Madrid, Valencia

  Age

  1 year to 17 years

  People

  70 worldwide

  Run by

  Incyte Biosciences International Sàrl

  See details and how to joinNCT03934372 · EU 2023-509699-41-00
• Phase 2Taking people
  A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

  Where

  Madrid, Salamanca

  Age

  18 years and over

  People

  60 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07709000 · EU 2025-522242-49-00
• Phase 3Not yet taking people in Spain
  ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  Where

  Barcelona, Madrid, Murcia, Oviedo, Santiago de Compostela, Sevilla

  Age

  18 years and over

  People

  306 worldwide

  Run by

  Newave Pharmaceutical Inc

  See details and how to joinNCT07342478 · EU 2026-525656-28-00
• Phase 1Taking people
  A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  Where

  Barcelona, Madrid, Pamplona

  People

  225 worldwide

  Run by

  Janssen Cilag International

  See details and how to join2026-525234-39-00
• Phase 3Taking people
  A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

  Where

  L'Hospitalet Del Llobregat, Pozuelo de Alarcón, Valencia

  Age

  18 years and over

  People

  735 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT05947851 · EU 2022-501560-17-00
• Phase 1Taking people
  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

  Where

  Barcelona

  Age

  18 years and over

  People

  332 worldwide

  Run by

  Hoffmann-La Roche

  See details and how to joinNCT05091424
• Phase 2Taking people
  A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  Where

  Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Marbella, Oviedo, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Sevilla

  Age

  18 years and over

  People

  249 worldwide

  Run by

  Loxo Oncology, Inc.

  See details and how to joinNCT06588478 · EU 2024-515689-15-01
• Phase 1Taking people
  A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

  Where

  Barcelona, Madrid, Pamplona, Salamanca

  Age

  18 years and over

  People

  120 worldwide

  Run by

  Janssen Research & Development, LLC

  See details and how to joinNCT06788509 · EU 2024-515457-21-00
• Phase 4Not yet taking people in Spain
  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  Where

  Santander, Seville

  Age

  18 years and over

  People

  150 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07218341
• Phase 4Taking people
  Acalabrutinib Monotherapy vs Investigator’s Choice of Treatment in Patients with Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment

  Where

  Barcelona, Madrid, Sevilla

  Age

  18 years and over

  People

  33 worldwide

  Run by

  AstraZeneca AB

  See details and how to join2023-510147-37-00
• Phase 1/2Taking people
  A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  Where

  Barcelona, Madrid, Palma, Santiago de Compostela, Valencia

  Age

  18 years and over

  People

  408 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06564038 · EU 2024-515034-33-00
• Phase 2Taking people
  Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

  Where

  A Coruña, Alicante, Barcelona, L'Hospitalet de Llobregat, Madrid, Salamanca

  Age

  18 years and over

  People

  490 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT04728893 · EU 2023-504931-42-00
• Phase 1/2Not yet taking people in Spain
  A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

  Where

  L'Hospitalet de Llobregat, Madrid, Salamanca

  Age

  18 years and over

  People

  258 worldwide

  Run by

  BeOne Medicines

  See details and how to joinNCT06697184 · EU 2024-518829-15-00
• Phase 3Taking people
  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  Where

  Barcelona, L'Hospitalet de Llobregat, Madrid, Marbella, Salamanca, Santander, Sevilla

  Age

  18 years and over

  People

  630 worldwide

  Run by

  BeOne Medicines

  See details and how to joinNCT06943872 · EU 2024-517131-52-00
• Phase 2Taking people
  MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

  Where

  Barcelona, Granada, Madrid, Majadahonda

  Age

  18 years to 130 years

  People

  80 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07024706 · EU 2024-518858-17-00
• Phase 3Not yet taking people in Spain
  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  Where

  Badalona, Barcelona, Elche, Madrid, Santander

  Age

  18 years and over

  People

  63 worldwide

  Run by

  CSL Behring

  See details and how to joinNCT07648264 · EU 2026-525626-38-00
• Phase 3Taking people
  A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  Where

  Barcelona, L'Hospitalet de Llobregat, Majadahonda, Pozuelo de Alarcón, Salamanca, San Cristobal De La Laguna

  Age

  18 years and over

  People

  1,200 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06136559 · EU 2022-501697-19-01
• Phase 1/2Taking people
  A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  Where

  Barcelona, Madrid, Majadahonda, Valencia

  Age

  18 years and over

  People

  689 worldwide

  Run by

  BeOne Medicines

  See details and how to joinNCT05006716 · EU 2022-502157-33-00
• Phase 3Taking people
  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  Where

  Alicante, Badalona, Barcelona, Córdoba, Donostia, Las Palmas De Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Marbella, Murcia, Oviedo, Salamanca, Santander, Santiago de Compostela, Sevilla, Valencia, Zaragoza

  Age

  18 years and over

  People

  746 worldwide

  Run by

  University Of Cologne

  See details and how to join2023-510294-34-00
• Phase 3Taking people
  A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

  Where

  Badalona, Cáceres, Madrid, Pamplona, Valencia, Clinica Universidad De Navarra, Hospital Universitario Quironsalud Madrid

  Age

  18 years and over

  People

  49 worldwide

  Run by

  Grifols Biologicals, LLC

  See details and how to joinNCT07582432 · EU 2026-526803-31-00
• Phase 1/2Taking people
  A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  Where

  Barcelona, L'Hospitalet de Llobregat, Madrid

  Age

  18 years and over

  People

  174 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06542250
• Phase 3Taking people
  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  Where

  Badalona, Burgos, Las Palmas De Gran Canaria, Madrid, Majadahonda, Palma, Sevilla

  Age

  18 years and over

  People

  500 worldwide

  Run by

  BeOne Medicines

  See details and how to joinNCT06973187 · EU 2025-522860-34-00
• Phase 3Taking people
  A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  Where

  Granada, Madrid, Majadahonda, Murcia

  Age

  18 years and over

  People

  500 worldwide

  Run by

  BeOne Medicines

  See details and how to joinNCT07277231 · EU 2025-524366-21-00
• Phase 4Taking people
  Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

  Where

  Barcelona, Madrid, Seville

  Age

  18 years to 130 years

  People

  60 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06651970
• Phase 3Taking people
  A long-term follow-up study for patients treated with Galapagos CAR T cell therapies

  Where

  Barcelona

  Age

  18 years and over

  People

  309 worldwide

  Run by

  Lakefront Biotherapeutics

  See details and how to join2023-510173-34-00